192 related articles for article (PubMed ID: 11358853)
1. Loss of expression of a new member of the DNAJ protein family confers resistance to chemotherapeutic agents used in the treatment of ovarian cancer.
Shridhar V; Bible KC; Staub J; Avula R; Lee YK; Kalli K; Huang H; Hartmann LC; Kaufmann SH; Smith DI
Cancer Res; 2001 May; 61(10):4258-65. PubMed ID: 11358853
[TBL] [Abstract][Full Text] [Related]
2. Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.
Strathdee G; Davies BR; Vass JK; Siddiqui N; Brown R
Carcinogenesis; 2004 May; 25(5):693-701. PubMed ID: 14729589
[TBL] [Abstract][Full Text] [Related]
3. Demethylation of the MCJ gene in stage III/IV epithelial ovarian cancer and response to chemotherapy.
Strathdee G; Vass JK; Oien KA; Siddiqui N; Curto-Garcia J; Brown R
Gynecol Oncol; 2005 Jun; 97(3):898-903. PubMed ID: 15894365
[TBL] [Abstract][Full Text] [Related]
4. Methylation-controlled J protein promotes c-Jun degradation to prevent ABCB1 transporter expression.
Hatle KM; Neveu W; Dienz O; Rymarchyk S; Barrantes R; Hale S; Farley N; Lounsbury KM; Bond JP; Taatjes D; Rincón M
Mol Cell Biol; 2007 Apr; 27(8):2952-66. PubMed ID: 17283040
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic silencing of HSulf-1 in ovarian cancer:implications in chemoresistance.
Staub J; Chien J; Pan Y; Qian X; Narita K; Aletti G; Scheerer M; Roberts LR; Molina J; Shridhar V
Oncogene; 2007 Jul; 26(34):4969-78. PubMed ID: 17310998
[TBL] [Abstract][Full Text] [Related]
6. Hypomethylation of the synuclein gamma gene CpG island promotes its aberrant expression in breast carcinoma and ovarian carcinoma.
Gupta A; Godwin AK; Vanderveer L; Lu A; Liu J
Cancer Res; 2003 Feb; 63(3):664-73. PubMed ID: 12566312
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic inactivation of MCJ (DNAJD1) in malignant paediatric brain tumours.
Lindsey JC; Lusher ME; Strathdee G; Brown R; Gilbertson RJ; Bailey S; Ellison DW; Clifford SC
Int J Cancer; 2006 Jan; 118(2):346-52. PubMed ID: 16049974
[TBL] [Abstract][Full Text] [Related]
8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
9. Contribution of epigenetic silencing of tumor necrosis factor-related apoptosis inducing ligand receptor 1 (DR4) to TRAIL resistance and ovarian cancer.
Horak P; Pils D; Haller G; Pribill I; Roessler M; Tomek S; Horvat R; Zeillinger R; Zielinski C; Krainer M
Mol Cancer Res; 2005 Jun; 3(6):335-43. PubMed ID: 15972852
[TBL] [Abstract][Full Text] [Related]
10. RPS6KA2, a putative tumour suppressor gene at 6q27 in sporadic epithelial ovarian cancer.
Bignone PA; Lee KY; Liu Y; Emilion G; Finch J; Soosay AE; Charnock FM; Beck S; Dunham I; Mungall AJ; Ganesan TS
Oncogene; 2007 Feb; 26(5):683-700. PubMed ID: 16878154
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic and genetic alterations of p33ING1b in ovarian cancer.
Shen DH; Chan KY; Khoo US; Ngan HY; Xue WC; Chiu PM; Ip P; Cheung AN
Carcinogenesis; 2005 Apr; 26(4):855-63. PubMed ID: 15677627
[TBL] [Abstract][Full Text] [Related]
12. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
13. Reduced expression of intercellular adhesion molecule-1 in ovarian adenocarcinomas.
Arnold JM; Cummings M; Purdie D; Chenevix-Trench G
Br J Cancer; 2001 Nov; 85(9):1351-8. PubMed ID: 11720474
[TBL] [Abstract][Full Text] [Related]
14. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
Villedieu M; Louis MH; Dutoit S; Brotin E; Lincet H; Duigou F; Staedel C; Gauduchon P; Poulain L
Gynecol Oncol; 2007 Apr; 105(1):31-44. PubMed ID: 17275076
[TBL] [Abstract][Full Text] [Related]
15. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers.
Yuan J; Luo RZ; Fujii S; Wang L; Hu W; Andreeff M; Pan Y; Kadota M; Oshimura M; Sahin AA; Issa JP; Bast RC; Yu Y
Cancer Res; 2003 Jul; 63(14):4174-80. PubMed ID: 12874023
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of TSLC1 gene in nasopharyngeal carcinoma.
Hui AB; Lo KW; Kwong J; Lam EC; Chan SY; Chow LS; Chan AS; Teo PM; Huang DP
Mol Carcinog; 2003 Dec; 38(4):170-8. PubMed ID: 14639656
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of FEZ1/LZTS1 gene with frequent loss of heterozygosity in oral squamous cell carcinomas.
Ono K; Uzawa K; Nakatsuru M; Shiiba M; Mochida Y; Tada A; Bukawa H; Miyakawa A; Yokoe H; Tanzawa H
Int J Oncol; 2003 Aug; 23(2):297-302. PubMed ID: 12851677
[TBL] [Abstract][Full Text] [Related]
18. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
[TBL] [Abstract][Full Text] [Related]
19. Elevated MAL expression is accompanied by promoter hypomethylation and platinum resistance in epithelial ovarian cancer.
Lee PS; Teaberry VS; Bland AE; Huang Z; Whitaker RS; Baba T; Fujii S; Secord AA; Berchuck A; Murphy SK
Int J Cancer; 2010 Mar; 126(6):1378-89. PubMed ID: 19642140
[TBL] [Abstract][Full Text] [Related]
20. Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma.
Lee MG; Kim HY; Byun DS; Lee SJ; Lee CH; Kim JI; Chang SG; Chi SG
Cancer Res; 2001 Sep; 61(18):6688-92. PubMed ID: 11559536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
